Molecule
IL-13
Effector cytokine / tissue remodeller
- Expression change
- Elevated
- Evidence level
- established
- Targeted by
- Dupilumab (via IL-4Rα blockade)
Role in pathogenesis
IL-13 drives goblet cell hyperplasia, MUC5AC mucus production, epithelial barrier disruption, and subepithelial fibrosis. Shares IL-4Rα receptor with IL-4. Central to polyp tissue remodelling and oedema formation.
Targeting drugs (1)
| Drug | Mechanism | Response rate | Line |
|---|---|---|---|
| Dupilumab | Anti–IL-4Rα monoclonal antibody (blocks IL-4 and IL-13) | ~75% polyp reduction | 1st-line biologic |